Bright Minds Biosciences

Bright Minds Biosciences is a clinical-stage biotechnology company designing highly selective serotonin 5-HT2 receptor agonists for drug-resistant epilepsy, neuropsychiatry and other central nervous system disorders. Its lead candidate BMB-101 is a 5-HT2C agonist in Phase 2 development for developmental and epileptic encephalopathies and absence epilepsies, built to be more selective for 5-HT2C relative to 5-HT2A and 5-HT2B so that it can be dosed chronically without the hallucinogenic and cardiac liabilities of less selective serotonergic drugs. The pipeline also includes BMB-105 for Prader-Willi syndrome and the BMB-201 and BMB-202 programmes in neuropsychiatric and neurological indications, and the company collaborates with Firefly Neuroscience on electroencephalogram analysis from its BREAKTHROUGH study. In November 2026 the U.S. Food and Drug Administration placed a partial clinical hold on the planned Phase 2 DEE trial and its IND, citing toxicity observed in mice and insufficient pharmacokinetic and juvenile-toxicity data to support enrolment of paediatric patients; the company has said ongoing trials are unaffected and that it believes the mouse finding was incidental. Bright Minds was founded in 2017, is headquartered in New York, and its common stock trades on Nasdaq under the symbol DRUG.